Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rating Increased to Strong-Buy at Zacks Research

Key Points

• Bayer Aktiengesellschaft's rating was upgraded to Strong-Buy by Zacks Research, indicating strong analyst confidence in the stock.
• Multiple analysts, including firms like Goldman Sachs and Wall Street Zen, have also raised their ratings on Bayer to Strong-Buy recently, reflecting a positive outlook for the company.
• Bayer's stock increased by 4.9% and closed at $8.70, with a market capitalization of $34.19 billion and a reported earnings per share of $0.35, which surpassed analysts' expectations.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was upgraded by stock analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a note issued to investors on Tuesday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Wall Street Zen raised shares of Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. The Goldman Sachs Group upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. Hsbc Global Res raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, June 11th. Finally, Kepler Capital Markets upgraded Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday, June 11th. Three investment analysts have rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to MarketBeat.com, Bayer Aktiengesellschaft currently has an average rating of "Strong Buy".

Bayer Aktiengesellschaft Stock Up 4.9%

Shares of OTCMKTS:BAYRY opened at $8.70 on Tuesday. The firm has a market capitalization of $34.19 billion, a P/E ratio of -8.97, a P/E/G ratio of 3.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. The stock has a 50 day moving average price of $8.06 and a 200-day moving average price of $7.32. Bayer Aktiengesellschaft has a 52-week low of $4.79 and a 52-week high of $8.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of $0.25 by $0.10. The company had revenue of $12.42 billion for the quarter, compared to analysts' expectations of $10.79 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.44% and a negative net margin of 7.61%. As a group, equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.31 EPS for the current fiscal year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.